Population pharmacokinetics of hydroxyurea in cancer patients

[1]  F. Martin,et al.  Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat , 1992, Pharmaceutical Research.

[2]  Chien-Fang Yang,et al.  Transcatheter arterial chemoembolization for hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[3]  B. Cantwell,et al.  Phase 1 study of high-dose hydroxyurea in lung cancer , 2004, Cancer Chemotherapy and Pharmacology.

[4]  W. Vaughan,et al.  Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4′-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model , 2004, Cancer Chemotherapy and Pharmacology.

[5]  B. Edwards,et al.  High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. , 1994, Bone marrow transplantation.

[6]  P. Gwilt,et al.  Pharmacokinetics of hydroxyurea in the rat , 1992 .

[7]  George J. Dover,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments] , 1992 .

[8]  M. Vacca,et al.  Hydroxyurea: relationship between toxicity and centrally-induced adrenal activation. , 1990, Pharmacology & toxicology.

[9]  T. Ley,et al.  Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. , 1986, Blood.

[10]  A. Holmberg.  On the practical identifiability of microbial growth models incorporating Michaelis-Menten type nonlinearities , 1982 .

[11]  R. Belt,et al.  Studies of hydroxyurea administered by continuous infusion. Toxicity, pharmacokinetics, and cell synchronization , 1980, Cancer.

[12]  C. Metzler,et al.  Mathematical properties of compartment models with Michaelis-Menton type elimination , 1980 .

[13]  M. Nihtilä,et al.  Practical identifiability of growth and substrate consumption models , 1977, Biotechnology and bioengineering.

[14]  E. Fabricius,et al.  Determination of hydroxyurea in mammalian tissues and blood. , 1971, Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research.

[15]  M. Colvin,et al.  The enzymatic reduction of hydroxyurea to urea by mouse liver. , 1970, Cancer research.

[16]  H. Elford.  Effect of hydroxyurea on ribonucleotide reductase. , 1968, Biochemical and biophysical research communications.

[17]  H. S. Schwartz,et al.  Hydroxyurea. I. Acute cell death in proliferating tissues in rats. , 1967, Cancer research.

[18]  R. Adamson,et al.  The distribution, excretion and metabolism of hydroxyurea-C14. , 1965, The Journal of pharmacology and experimental therapeutics.

[19]  H. Lerner,et al.  Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. , 1965, Cancer chemotherapy reports.